αDC1

αDC1 is an autologous cell therapy consisting of alpha-type-1-polarized dendritic cells (αDC1), which are generated from a patient's own monocytes and matured ex vivo under specific cytokine conditions to promote a type 1 immune response. These cells are loaded with tumor antigens (such as peptides derived from HER2/HER3 or other tumor-associated proteins) and administered as a therapeutic cancer vaccine. The primary mechanism involves the induction of strong cytotoxic T lymphocyte (CTL) and T-helper 1 (Th1) responses against tumor antigens, facilitated by the secretion of chemokines like CXCL9, CXCL10, CXCL11, and CCL5 that attract effector immune cells to the tumor microenvironment. Clinical studies have evaluated αDC1 in combination with chemokine modulation regimens or checkpoint inhibitors for various cancers including metastatic colorectal cancer, peritoneal surface malignancies after surgery, triple negative breast cancer with brain metastases, and gliomas[2][4][5][1].

Other names

αDC1 vaccinealpha-type-1-polarized dendritic cell vaccinealpha-type1-polarized dendritic cell vaccinealpha-type 1-polarized dendritic cell vaccine